Evidence map›Paper›PMID 31222183›Full record

ReviewCancer gene therapy2020

Translatable gene therapy for lung cancer using Crispr CAS9-an exploratory review.

Jishnu Nair, Abhishek Nair, Soundaram Veerappan, Dwaipayan Sen

Abstract readReview
PubMed Publisher
In one paragraph

Review in Cancer gene therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. CRISPR-Cas9-mediated gene therapy in lung cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023
    Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jishnu NairCellular and Molecular Therapeutics Laboratory, Center for Biomaterials, Cellular and Molecular Theranostics, Vellore Institute of Technology, Vellore, Tamil Nadu, 632014, India.ORCID http://orcid.org/0000-0002-0186-7672
Abhishek NairCellular and Molecular Therapeutics Laboratory, Center for Biomaterials, Cellular and Molecular Theranostics, Vellore Institute of Technology, Vellore, Tamil Nadu, 632014, India.
Soundaram VeerappanCellular and Molecular Therapeutics Laboratory, Center for Biomaterials, Cellular and Molecular Theranostics, Vellore Institute of Technology, Vellore, Tamil Nadu, 632014, India.ORCID http://orcid.org/0000-0003-0828-0839
Dwaipayan SenCellular and Molecular Therapeutics Laboratory, Center for Biomaterials, Cellular and Molecular Theranostics, Vellore Institute of Technology, Vellore, Tamil Nadu, 632014, India. dwaipayan.sen@vit.ac.in.ORCID http://orcid.org/0000-0002-3485-494X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gene therapy using CRISPR Cas9 technique is rapidly gaining popularity among the scientific community primarily because of its versatility, cost-effectiveness, and high efficacy. While the laboratory-based experiments and findings making use of CRISPR as a gene editing tool are available in ample amounts, the question arises that how much of these findings are actually translatable into measures helping in combating particular disease conditions. In this review, we highlight the important studies and findings done till now in the perspective of lung cancer with an in-depth analysis of various clinical trials associated with the use of CRISPR Cas9 technology in the field of cancer research.

Indexed as

AnimalsBiomarkers, TumorCarcinoma, Non-Small-Cell LungCell Line, TumorChromosomes, Human, Pair 3Chromosomes, Human, Pair 5Chromosomes, Human, Pair 9Clinical Trials as TopicCRISPR-Cas SystemsGene EditingGene Knockout TechniquesGenetic TherapyHumansLung NeoplasmsMiceMutationBiomarkers, TumorTumor Suppressor Proteins

Identifiers

PMID31222183

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.